Polymeric carriers and methods

US11560545B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11560545-B2
Application numberUS-201816610325-A
CountryUS
Kind codeB2
Filing dateMay 1, 2018
Priority dateMay 2, 2017
Publication dateJan 24, 2023
Grant dateJan 24, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are methods of controlling disassociation of cells from a carrier, compositions, and methods of collecting cells. The methods of controlling disassociation of cells from a carrier may include contacting a polymeric carrier with one or more digesting agents to disassociate at least a portion of a plurality of cells from the polymeric carrier. The polymeric carrier may be crosslinked with a crosslinker including at least one of a redox sensitive moiety, a UV light sensitive moiety, a pH sensitive moiety, and a temperature sensitive moiety.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of controlling disassociation of cells from a carrier, the method comprising: providing a polymeric carrier and a plurality of cells adhered to the polymeric carrier, wherein the polymeric carrier is a microcarrier; and contacting the polymeric carrier with one or more digesting agents to disassociate at least a portion of the plurality of cells from the polymeric carrier; wherein the polymeric carrier comprises gelatin, and is crosslinked with a crosslinker comprising at least one redox sensitive moiety, wherein the at least one redox sensitive moiety comprises a disulfide bond, and the crosslinker comprises a compound having the following structure— wherein R 1 and R 2 are independently selected from a divalent C 1 -C 20 hydrocarbyl. 2. The method of claim 1 , wherein R 1 and R 2 are unsubstituted divalent C 1 -C 5 hydrocarbyls, and the crosslinker has the following structure: 3. The method of claim 1 , wherein R 1 and R 2 are unsubstituted divalent C 2 hydrocarbyls, and the crosslinker comprises 1,2-bis-(2-isocyanatoethyl)disulfide (DIDS): 4. The method of claim 1 , wherein the plurality of cells comprises human Mesenchymal stem cells (hMSCs), endothelial cells, or a combination thereof. 5. The method of claim 1 , wherein the polymeric carrier further comprises dextran, hyaluronic acid, agarose, chitosan, alginate, polyvinyl alcohol, polyamino acid, calcium alginate, polyacrylate, polyethylene glycol, polyethylene imine, polyanhydride, or a combination thereof. 6. The method of claim 1 , wherein the polymeric carrier further comprises dextran, hyaluronic acid, agarose, chitosan, alginate, polyvinyl alcohol, polyamino acid, or a combination thereof. 7. The method of claim 1 , wherein the polymeric carrier is a polymeric carrier bead. 8. The method of claim 1 , wherein the one or more digesting agents comprises a reducing agent. 9. The method of claim 8 , wherein the reducing agent comprises dithiothreitol (DTT), cysteine, glutathione, or a combination thereof. 10. The method of claim 8 , wherein the reducing agent comprises a solution of dithiothreitol (DTT) having a concentration of about 5 mM to about 25 mM. 11. The method of claim 10 , wherein the solution of dithiothreitol further comprises sodium citrate, trypsin, or a combination thereof. 12. The method of claim 1 , wherein the one or more digesting agents comprises an enzyme. 13. The method of claim 12 , wherein the enzyme comprises collagenase, dispase-like protease, trypsin, urease, papain, bromelain, pancreatin, gelatinase (MMP2 and MMP9), or a combination thereof. 14. The method of claim 1 , wherein the one or more digesting agents comprises a reducing agent and an enzyme. 15. The method of claim 1 , wherein the ratio of the crosslinker (mmol) to the polymeric carrier (g) is about 0.1 mmol:10 g to about 1.9 mmol:10 g.

Assignees

Inventors

Classifications

  • Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title

  • Alginic acid; Derivatives thereof · CPC title

  • Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers · CPC title

  • Cross-linking · CPC title

  • Crosslinking · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11560545B2 cover?
Provided are methods of controlling disassociation of cells from a carrier, compositions, and methods of collecting cells. The methods of controlling disassociation of cells from a carrier may include contacting a polymeric carrier with one or more digesting agents to disassociate at least a portion of a plurality of cells from the polymeric carrier. The polymeric carrier may be crosslinked wit…
Who is the assignee on this patent?
Brigham & Womens Hospital Inc, Lonza Walkersville Inc, Massachusetts Inst Technology
What technology area does this patent fall under?
Primary CPC classification C12N5/0075. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).